Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.

17α-Estradiol Alleviates Age-related Metabolic and Inflammatory Dysfunction in Male Mice Without Inducing Feminization

Open access
Stout, Michael B., Steyn, Frederik J., Jurczak, Michael J., Camporez, Joao-Paulo G., Zhu, Yi, Hawse, John R., Jurk, Diana, Palmer, Allyson K., Xu, Ming, Pirtskhalava, Tamar, Evans, Glenda L., de Souza Santos, Roberta, Frank, Aaron P., White, Thomas A., Monroe, David G., Singh, Ravinder J., Casaclang-Verzosa, Grace, Miller, Jordan D., Clegg, Deborah J., LeBrasseur, Nathan K., von Zglinicki, Thomas, Shulman, Gerald I., Tchkonia, Tamara, Kirkland, James L. · 2017 · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences

Abstract

Aging is associated with visceral adiposity, metabolic disorders, and chronic low-grade inflammation. 17α-estradiol (17α-E2), a naturally occurring enantiomer of 17β-estradiol (17β-E2), extends life span in male mice through unresolved mechanisms. We tested whether 17α-E2 could alleviate age-related metabolic dysfunction and inflammation. 17α-E2 reduced body mass, visceral adiposity, and ectopic lipid deposition without decreasing lean mass. These declines were associated with reductions in energy intake due to the activation of hypothalamic anorexigenic pathways and direct effects of 17α-E2 on nutrient-sensing pathways in visceral adipose tissue. 17α-E2 did not alter energy expenditure or excretion. Fasting glucose, insulin, and glycosylated hemoglobin were also reduced by 17α-E2, and hyperinsulinemic-euglycemic clamps revealed improvements in peripheral glucose disposal and hepatic glucose production. Inflammatory mediators in visceral adipose tissue and the circulation were reduced by 17α-E2. 17α-E2 increased AMPKα and reduced mTOR complex 1 activity in visceral adipose tissue but not in liver or quadriceps muscle, which is in contrast to the generalized systemic effects of caloric restriction. These beneficial phenotypic changes occurred in the absence of feminization or cardiac dysfunction, two commonly observed deleterious effects of exogenous estrogen administration. Thus, 17α-E2 holds potential as a novel therapeutic for alleviating age-related metabolic dysfunction through tissue-specific effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/gerona/glv309

Cites

92 of 92 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. 17α-E2 reduces body mass and adiposity. Weekly changes in (A) total body mass, (B) fat mass, and (C) lean mass in CON (blue) and 17α-E2 (red) treatment groups from Study 1. Representative cross-sectional images of visceral (pink) and subcutaneous (gray) adiposity in the lumbar region of (D) CON and (E) 17α-E2 treatment groups at Week 12 of Study 1. (F) Quantitative analysis of regional adiposity in the lumbar region from CON and 17α-E2 treatment groups from Study 1. (G) Plasma leptin and (H) plasma leptin normalized to total, lean, and fat mass from CON and 17α-E2 treatment groups from Study 1. (I) Plasma adiponectin and (J) plasma adiponectin normalized to total, lean, and fat mass from CON and 17α-E2 treatment groups from Study 1. Daily changes in (K) total body mass and weekly changes in (L) lean:fat mass ratios in CON (yellow), 17α-E2 (orange), and calorie restriction (green) treatment groups from Study 2. All data are expressed as mean ± SEM of 7–10 mice per treatment group and were analyzed by repeated measures analysis of variance (A–C, K, L) or Student’s t test (F–J). *p < .05. # p < .01. $ p < .005.
Figure 1. 17α-E2 reduces body mass and adiposity. Weekly changes in (A) total body mass, (B) fat mass, and (C) lean mass in CON (blue) and 17α-E2 (red) treatment groups from Study 1. Representative cross-sectional images of visceral (pink) and subcutaneous (gray) adiposity in the lumbar region of (D) CON and (E) 17α-E2 treatment groups at Week 12 of Study 1. (F) Quantitative analysis of regional adiposity in the lumbar region from CON and 17α-E2 treatment groups from Study 1. (G) Plasma leptin and (H) plasma leptin normalized to total, lean, and fat mass from CON and 17α-E2 treatment groups from Study 1. (I) Plasma adiponectin and (J) plasma adiponectin normalized to total, lean, and fat mass from CON and 17α-E2 treatment groups from Study 1. Daily changes in (K) total body mass and weekly changes in (L) lean:fat mass ratios in CON (yellow), 17α-E2 (orange), and calorie restriction (green) treatment groups from Study 2. All data are expressed as mean ± SEM of 7–10 mice per treatment group and were analyzed by repeated measures analysis of variance (A–C, K, L) or Student’s t test (F–J). *p < .05. # p < .01. $ p < .005.CC BY-NC · PubMed Central
Figure 2. 17α-E2 reduces energy intake but not expenditure or excretion. (A) Oxygen consumption, (B) energy expenditure, and (C) voluntary activity during Weeks 0 and 12 from CON (blue) and 17α-E2 (red) treatment groups from Study 1. (D) Oxygen consumption, (E) energy expenditure, and (F) voluntary activity during Week 4 from CON (yellow), 17α-E2 (orange), and calorie restriction (CR; green) treatment groups from Study 2. (G) Fecal energy excretion during Weeks 0 and 5 from CON, 17α-E2, and CR treatment groups from Study 2. (I) Daily calorie intake per week and total calories consumed from CON, 17α-E2, and CR treatment groups from Study 2. (J) Daily calorie intake per week normalized to body mass and total calories consumed normalized to body mass from CON, 17α-E2, and CR treatment groups from Study 2. (K) Anorexigenic gene expression in the hypothalamus from CON, 17α-E2, and CR treatment groups from Study 2. All data are expressed as mean ± SEM of 7–10 mice per treatment group and were analyzed by Student’s t test (A–C) or one-way analysis of variance (D–K). ♦ p < .05 (different from nonlabeled groups).
Figure 2. 17α-E2 reduces energy intake but not expenditure or excretion. (A) Oxygen consumption, (B) energy expenditure, and (C) voluntary activity during Weeks 0 and 12 from CON (blue) and 17α-E2 (red) treatment groups from Study 1. (D) Oxygen consumption, (E) energy expenditure, and (F) voluntary activity during Week 4 from CON (yellow), 17α-E2 (orange), and calorie restriction (CR; green) treatment groups from Study 2. (G) Fecal energy excretion during Weeks 0 and 5 from CON, 17α-E2, and CR treatment groups from Study 2. (I) Daily calorie intake per week and total calories consumed from CON, 17α-E2, and CR treatment groups from Study 2. (J) Daily calorie intake per week normalized to body mass and total calories consumed normalized to body mass from CON, 17α-E2, and CR treatment groups from Study 2. (K) Anorexigenic gene expression in the hypothalamus from CON, 17α-E2, and CR treatment groups from Study 2. All data are expressed as mean ± SEM of 7–10 mice per treatment group and were analyzed by Student’s t test (A–C) or one-way analysis of variance (D–K). ♦ p < .05 (different from nonlabeled groups).CC BY-NC · PubMed Central
Figure 3. 17α-E2 reduces inflammation in white adipose tissue (WAT) and the circulation. Pro-inflammatory gene expression in (A) subcutaneous (iWAT) and (B) visceral (eWAT) WAT from CON (blue) and 17α-E2 (red) treatment groups from Study 1. Representative images of SA-βgal+ in iWAT from (C) CON and (D) 17α-E2 treatment groups from Study 1. (E) Percent SA-βgal+ in iWAT from CON and 17α-E2 treatment groups from Study 1. (F) SA-mRNA expression in iWAT from CON and 17α-E2 treatment groups from Study 1. Representative images of SA-βgal+ in eWAT from (G) CON and (H) 17α-E2 treatment groups from Study 1. (I) Percent SA-βgal+ in eWAT from CON and 17α-E2 treatment groups from Study 1. (J) SA-mRNA expression in eWAT from CON and 17α-E2 treatment groups from Study 1. (K) Plasma pro-inflammatory cytokines and chemokines in CON and 17α-E2 treatment groups at Week 15 of Study 1. Arrows indicate SA-βgal+ activity in representative samples. All data are expressed as mean ± SEM of 8–10 mice per treatment group and were analyzed by Student’s t test. *p < .05. # p < .01. $ p < .005. Scale bars: 50 µm.
Figure 3. 17α-E2 reduces inflammation in white adipose tissue (WAT) and the circulation. Pro-inflammatory gene expression in (A) subcutaneous (iWAT) and (B) visceral (eWAT) WAT from CON (blue) and 17α-E2 (red) treatment groups from Study 1. Representative images of SA-βgal+ in iWAT from (C) CON and (D) 17α-E2 treatment groups from Study 1. (E) Percent SA-βgal+ in iWAT from CON and 17α-E2 treatment groups from Study 1. (F) SA-mRNA expression in iWAT from CON and 17α-E2 treatment groups from Study 1. Representative images of SA-βgal+ in eWAT from (G) CON and (H) 17α-E2 treatment groups from Study 1. (I) Percent SA-βgal+ in eWAT from CON and 17α-E2 treatment groups from Study 1. (J) SA-mRNA expression in eWAT from CON and 17α-E2 treatment groups from Study 1. (K) Plasma pro-inflammatory cytokines and chemokines in CON and 17α-E2 treatment groups at Week 15 of Study 1. Arrows indicate SA-βgal+ activity in representative samples. All data are expressed as mean ± SEM of 8–10 mice per treatment group and were analyzed by Student’s t test. *p < .05. # p < .01. $ p < .005. Scale bars: 50 µm.CC BY-NC · PubMed Central
Figure 4. 17α-E2 reverses age-related lipid redistribution and improves glucose homeostasis. Representative images of total hepatic lipid content from (A) CON and (B) 17α-E2 treatment groups from Study 1. Triglyceride accumulation in (C) liver and (D) quadriceps from CON (blue) and 17α-E2 (red) treatment groups from Study 1. (E) Fasting glucose at Weeks 0 and 15 in CON and 17α-E2 treatment groups from Study 1. (F) Fasting insulin and (G) Glycosylated hemoglobin (HbA1c) at Week 15 in CON and 17α-E2 treatment groups from Study 1. (H) Glucose tolerance at Week 10 in CON and 17α-E2 treatment groups from Study 1. (I) Glucose tolerance area under the curve at Week 10 in CON and 17α-E2 treatment groups from Study 1. (J) Fasting glucose at Weeks 0, 2, and 4 in CON (yellow), 17α-E2 (orange), and calorie restriction (CR; green) treatment groups from Study 2. (K) HbA1c at Weeks 0 and 5 in CON, 17α-E2, and CR treatment groups from Study 2. All data are expressed as mean ± SEM of 8–10 mice per treatment group and were analyzed by Student’s t test (C–G), repeated measures analysis of variance (ANOVA; H), or one-way ANOVA (J–K). *p < .05. # p < .01. $ p < .005. ♦ p < .05 (different from nonlabeled groups); ♠ p < .05 (different from nonlabeled and ♦-labeled groups). Scale bars: 200 µm.
Figure 4. 17α-E2 reverses age-related lipid redistribution and improves glucose homeostasis. Representative images of total hepatic lipid content from (A) CON and (B) 17α-E2 treatment groups from Study 1. Triglyceride accumulation in (C) liver and (D) quadriceps from CON (blue) and 17α-E2 (red) treatment groups from Study 1. (E) Fasting glucose at Weeks 0 and 15 in CON and 17α-E2 treatment groups from Study 1. (F) Fasting insulin and (G) Glycosylated hemoglobin (HbA1c) at Week 15 in CON and 17α-E2 treatment groups from Study 1. (H) Glucose tolerance at Week 10 in CON and 17α-E2 treatment groups from Study 1. (I) Glucose tolerance area under the curve at Week 10 in CON and 17α-E2 treatment groups from Study 1. (J) Fasting glucose at Weeks 0, 2, and 4 in CON (yellow), 17α-E2 (orange), and calorie restriction (CR; green) treatment groups from Study 2. (K) HbA1c at Weeks 0 and 5 in CON, 17α-E2, and CR treatment groups from Study 2. All data are expressed as mean ± SEM of 8–10 mice per treatment group and were analyzed by Student’s t test (C–G), repeated measures analysis of variance (ANOVA; H), or one-way ANOVA (J–K). *p < .05. # p < .01. $ p < .005. ♦ p < .05 (different from nonlabeled groups); ♠ p < .05 (different from nonlabeled and ♦-labeled groups). Scale bars: 200 µm.CC BY-NC · PubMed Central
Figure 5. 17α-E2 improves systemic insulin sensitivity. (A) Glucose and (B) insulin under basal and clamped conditions from CON (blue) and 17α-E2 (red) treatment groups from Study 1. (C) Real-time and (D) average glucose infusion rates (GIRs) from CON and 17α-E2 treatment groups from Study 1. (E) Whole-body glucose disposal, (F) endogenous glucose production (EGP) under basal and clamped conditions, and (G) hyperinsulinemia-induced percent EGP suppression from CON and 17α-E2 treatment groups from Study 1. (H) Tissue-specific disposal of 2-deoxyglucose during hyperinsulinemia from CON and 17α-E2 treatment groups from Study 1. (I) Circulating free fatty acids (FFAs) under basal and clamped conditions and (J) percent lipolysis suppression during hyperinsulinemia from CON and 17α-E2 treatment groups from Study 1. All data are expressed as mean ± SEM of 7 mice per treatment group and were analyzed by Student’s t test (A, B, D–J) or repeated-measures analysis of variance (c). *p < .05. $ p < .005.
Figure 5. 17α-E2 improves systemic insulin sensitivity. (A) Glucose and (B) insulin under basal and clamped conditions from CON (blue) and 17α-E2 (red) treatment groups from Study 1. (C) Real-time and (D) average glucose infusion rates (GIRs) from CON and 17α-E2 treatment groups from Study 1. (E) Whole-body glucose disposal, (F) endogenous glucose production (EGP) under basal and clamped conditions, and (G) hyperinsulinemia-induced percent EGP suppression from CON and 17α-E2 treatment groups from Study 1. (H) Tissue-specific disposal of 2-deoxyglucose during hyperinsulinemia from CON and 17α-E2 treatment groups from Study 1. (I) Circulating free fatty acids (FFAs) under basal and clamped conditions and (J) percent lipolysis suppression during hyperinsulinemia from CON and 17α-E2 treatment groups from Study 1. All data are expressed as mean ± SEM of 7 mice per treatment group and were analyzed by Student’s t test (A, B, D–J) or repeated-measures analysis of variance (c). *p < .05. $ p < .005.CC BY-NC · PubMed Central
Figure 6. 17α-E2 selectively activates AMPKα and suppresses mTOR complex 1. Representative Western blots of p-AMPKα, AMPKα, p-mTOR, mTOR, p-S6, S6, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from (A) visceral adipose (eWAT), (B) liver, and (C) quadriceps from CON and 17α-E2 treatment groups from Study 1. Densitometry results for p-AMPKα:AMPKα, p-mTOR:mTOR, and p-S6:S6 ratios from (D) visceral (eWAT), (E) liver, and (F) quadriceps from CON (blue) and 17α-E2 (red) treatment groups from Study 1. All data are expressed as mean ± SEM of 7–10 mice per treatment group and were analyzed by Student’s t test (D–F). $ p < .005.
Figure 6. 17α-E2 selectively activates AMPKα and suppresses mTOR complex 1. Representative Western blots of p-AMPKα, AMPKα, p-mTOR, mTOR, p-S6, S6, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from (A) visceral adipose (eWAT), (B) liver, and (C) quadriceps from CON and 17α-E2 treatment groups from Study 1. Densitometry results for p-AMPKα:AMPKα, p-mTOR:mTOR, and p-S6:S6 ratios from (D) visceral (eWAT), (E) liver, and (F) quadriceps from CON (blue) and 17α-E2 (red) treatment groups from Study 1. All data are expressed as mean ± SEM of 7–10 mice per treatment group and were analyzed by Student’s t test (D–F). $ p < .005.CC BY-NC · PubMed Central
Figure 7. 17α-E2 does not feminize male mice. (A) Gonadal, (B) seminiferous tubule, and (C) breast mass during necropsy from CON (blue) and 17α-E2 (red) treatment groups from Study 1. Plasma (D) testosterone, (E) 17β-E2, and (F) 17α-E2 in CON and 17α-E2 treatment groups at Week 15 of Study 1. (G) ERα and (H) ERβ mRNA expression in liver, quadriceps, subcutaneous and visceral WAT from CON and 17α-E2 treatment groups from Study 1. All data are expressed as mean ± SEM of 8–10 mice per treatment group and were analyzed by Student’s t test. *p < .05. $ p < .005.
Figure 7. 17α-E2 does not feminize male mice. (A) Gonadal, (B) seminiferous tubule, and (C) breast mass during necropsy from CON (blue) and 17α-E2 (red) treatment groups from Study 1. Plasma (D) testosterone, (E) 17β-E2, and (F) 17α-E2 in CON and 17α-E2 treatment groups at Week 15 of Study 1. (G) ERα and (H) ERβ mRNA expression in liver, quadriceps, subcutaneous and visceral WAT from CON and 17α-E2 treatment groups from Study 1. All data are expressed as mean ± SEM of 8–10 mice per treatment group and were analyzed by Student’s t test. *p < .05. $ p < .005.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 91 references

Cited by

See all 121

Metadata

Authors
Stout, M. B., Steyn, F. J., Jurczak, M. J., Camporez, J.-P. G., Zhu, Y., Hawse, J. R., Jurk, D., Palmer, A. K., Xu, M., Pirtskhalava, T., Evans, G. L., de Souza Santos, R., Frank, A. P., White, T. A., Monroe, D. G., Singh, R. J., Casaclang-Verzosa, G., Miller, J. D., Clegg, D. J., LeBrasseur, N. K., von Zglinicki, T., Shulman, G. I., Tchkonia, T., & Kirkland, J. L.
Affiliations
  • Mayo Clinic (US)
  • The University of Queensland (AU)
  • University of Pittsburgh (US)
  • Newcastle University (GB)
  • Cedars-Sinai Medical Center (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
Kirkland, James L.
Venue
The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
Published
2016-01-24
Volume
72
Issue
1
Pages
3-15
ISSN
  • 1079-5006 (ISSN-L)
  • 1758-535X
OpenAlex
W2301706102
Cited by
119
References
91
Citations by year
2026: 4 · 2025: 12 · 2024: 17 · 2023: 10 · 2022: 18 · 2021: 8 · 2020: 10 · 2019: 13 · 2018: 6 · 2017: 11 · 2016: 9
FWCI
10.47
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • The Journals of Gerontology Series A (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by-nc)
Funders
  • Yale University
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (2015/05801-7, 2015/)
  • National Institutes of Health (5p60dk079626-05, DK079626, DK059635, AG041122, DK-45735, DK050456, UL1TR001863)
  • Biotechnology and Biological Sciences Research Council (BB/I020748/1)
  • National Institute on Aging (F30AG046061, P01AG041122, K99AG051661, R00AG051661, R37AG013925)
  • National Heart, Lung, and Blood Institute (R01HL111121)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K01DK099402, P30DK050456, P60-DK-079626, R01DK040936, U24DK059635, P30DK056336, P30DK079626, P30DK045735)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
17α-estradiol, aging, visceral fat, metabolic dysfunction, low-grade inflammation, energy intake, visceral adipose tissue, ectopic fat deposition, glucose metabolism, insulin sensitivity, AMPK, mTOR, caloric restriction, male mice
MeSH terms
Aging, Animals, Estradiol, Estrogens, Feminization, Male, Mice, Inbred C57BL, Body Mass Index, Intra-Abdominal Fat, Adiposity, Lipid Metabolism, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 17α-Estradiol Alleviates Age-related Metabolic and Inflammatory Dysfunction in Male Mice Without Inducing Feminization. https://app.cochat.ai/papers/10.1093/gerona/glv309
The paper
Stout, M. B., Steyn, F. J., Jurczak, M. J., Camporez, J.-P. G., Zhu, Y., Hawse, J. R., Jurk, D., Palmer, A. K., Xu, M., Pirtskhalava, T., Evans, G. L., de Souza Santos, R., Frank, A. P., White, T. A., Monroe, D. G., Singh, R. J., Casaclang-Verzosa, G., Miller, J. D., Clegg, D. J., . . . Kirkland, J. L. (2017). 17α-Estradiol Alleviates Age-related Metabolic and Inflammatory Dysfunction in Male Mice Without Inducing Feminization. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. https://doi.org/10.1093/gerona/glv309

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.